17085-Myelofibrosis-NA-1278

Myelofibrosis

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Address

19646 N 27th Avenue, Suite 406
Phoenix, AZ 85027
P: (602) 357-2400

Find a Clinical Trial

Use the abbreviation for your state (ie. FL, TX, NV)
Search by practice name, trial titles, indicators and specific disease types.